UnicoCell Biomed Co (TPE:6794) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6794 UnicoCell Biomed Co Ltd TPE:6794
82 GF Score
Price NT$74.60
GF Value NT$81.16
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is UnicoCell Biomed Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of UnicoCell Biomed Co is: High Risk: High uncertainty with risk-return tradeoff.

UnicoCell Biomed Co  (TPE:6794) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

UnicoCell Biomed Co Risk Assessment Related Terms

TPE:6794 vs VRTX, REGN, RVMD: Risk Assessment Comparison

For the Biotechnology subindustry, UnicoCell Biomed Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UnicoCell Biomed Co Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where UnicoCell Biomed Co's Risk Assessment falls into.


TPE:6794
82GF Score
UnicoCell Biomed Co Ltd TPE:6794
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?

Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued. The current stock price of NT$74.60 is trading 8.1% below its estimated GF Value™ of NT$81.16. GuruFocus considers UnicoCell Biomed Co to be Fairly Valued.

Key valuation signals for TPE:6794:

  • Risk Assessment:
  • GF Value™: NT$81.16 vs. price of NT$74.60 (8.1% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UnicoCell Biomed Co Business Description

Address Minquan East Road, 5th Floor, No. 13-20, Section 6, Neihu District, Taipei, TWN, 11494
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
82GF Score

Get the complete analysis for TPE:6794

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$74.60
Price
NT$81.16
GF Value